Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
Event:
Date:
Time:
Location:
Webcast Link: Available by clicking here
Event: Cantor 2024 Global Healthcare Conference
Date:
Time:
Location:
Webcast Link: Available by clicking here
Company management will also be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your
Webcasts of the Company's presentations will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months.
About
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
+1-917-679-9282
tim@lifesciadvisors.com
Logo : https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-fireside-chats-at-two-investment-conferences-in-september-302240554.html
SOURCE Oncolytics Biotech® Inc.